Butterfly Network, Inc. (BFLY) Q2 2025 Earnings Call Transcript

Butterfly Network reported record Q2 2025 revenue of $23.4 million and an all-time high gross margin of 64%, alongside a 24% year-over-year improvement in adjusted EBITDA loss to $6.2 million and record low cash use of $7 million. Despite this strong operational performance, the company revised its full-year 2025 revenue guidance downward to $91M-$95M, attributing the adjustment to macro headwinds and extended sales cycles for large enterprise and global health deals due to healthcare funding uncertainties, while simultaneously improving its full-year adjusted EBITDA loss outlook to $32M-$37M through continued fiscal discipline. Key strategic initiatives, including the upcoming Compass AI software launch, commercialization of Butterfly Garden AI tools, and a successful HomeCare pilot demonstrating significant readmission reduction and substantial revenue potential, underscore the company's long-term growth strategy and market positioning amidst near-term market adjustments.

Analysis

Butterfly Network, Inc. (BFLY) demonstrated strong operational execution in its second quarter of 2025, delivering record quarterly revenue of $23.4 million, a 9% year-over-year increase, and an all-time high gross margin of 64%. The company significantly improved its financial discipline, reducing its adjusted EBITDA loss by 24% to $6.2 million and achieving a record-low quarterly cash use of $7 million. Despite these positive operational metrics, management has revised its full-year 2025 revenue guidance downward to a range of $91 million to $95 million. This revision is attributed to macroeconomic headwinds and healthcare funding uncertainties which have lengthened sales cycles for large enterprise and publicly funded global health deals, not competitive pressures. This is counterbalanced by a $5 million positive revision to its full-year adjusted EBITDA loss guidance, now projected at $32 million to $37 million, underscoring rigorous expense control. The company's strategic initiatives show significant promise, with the upcoming launch of its Compass AI software platform to drive enterprise adoption, the commercialization of its Butterfly Garden AI marketplace, and a highly successful HomeCare pilot. The HomeCare initiative, which proved to significantly reduce hospital readmissions, is moving toward a commercial agreement with a single partner that could represent a $40 million to $60 million revenue opportunity if scaled nationwide, signaling a potentially transformative new growth vector.

Key Decisions for Investors

• Investors should weigh the company's demonstrated operational leverage, including record gross margins and reduced cash burn, against the near-term revenue uncertainty caused by delayed large-scale customer purchasing decisions.
• It is prudent to closely monitor the execution of key growth catalysts in the second half of the year, particularly the signing of the first commercial HomeCare agreement and the market adoption of the new Compass AI software platform.
• Given the revised revenue outlook, investors should assess the company's capital runway of $152 million and its disciplined expense management in the context of its ability to fund long-term initiatives like the P5 chip development and HomeCare expansion without near-term dilution.
• Consider the potential for significant long-term upside from the HomeCare and Butterfly Garden initiatives, which aim to expand the addressable market and create high-margin, recurring revenue streams, but recognize these are still in the early stages of commercialization.